WallStSmart

Abbott Laboratories (ABT)vsLivaNova PLC (LIVN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 3049% more annual revenue ($45.13B vs $1.43B). ABT leads profitability with a 13.9% profit margin vs 7.5%. LIVN appears more attractively valued with a PEG of 0.91. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

LIVN

Buy

52

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 6.0Quality: 5.5
Piotroski: 4/9Altman Z: 0.35
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
LIVNUndervalued (+6.1%)

Margin of Safety

+6.1%

Fair Value

$70.73

Current Price

$72.36

$1.63 discount

UndervaluedFair: $70.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

LIVN2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.918/10

Growing faster than its price suggests

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

LIVN4 concerns · Avg: 2.3/10
Profit MarginProfitability
7.5%3/10

7.5% margin — thin

P/E RatioValuation
40.5x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.6%2/10

Earnings declined 45.6%

Altman Z-ScoreHealth
0.352/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : LIVN

The strongest argument for LIVN centers on Debt/Equity, PEG Ratio. Revenue growth of 14.3% demonstrates continued momentum. PEG of 0.91 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : LIVN

The primary concerns for LIVN are Profit Margin, P/E Ratio, EPS Growth. A P/E of 40.5x leaves little room for execution misses.

Key Dynamics to Monitor

LIVN carries more volatility with a beta of 0.88 — expect wider price swings.

LIVN is growing revenue faster at 14.3% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (56/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

LivaNova PLC

HEALTHCARE · MEDICAL DEVICES · USA

LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?